Evidence map›Paper›PMID 40861316›Full record

ArticleTherapeutic advances in medical oncology2025

Tissue factor expression in salivary gland carcinoma: a potential novel therapeutic target for advanced disease.

Louis Jansen, Lisa Nachtsheim, Philipp Wolber, Sami Shabli, Julia Eßer, Alexander Quaas, Luc G T Morris, Alan L Ho, Jens Peter Klußmann, Christoph Arolt and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Louis JansenDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0003-0332-1099
Lisa NachtsheimDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Philipp WolberDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Sami ShabliDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Julia EßerDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Alexander QuaasCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Luc G T MorrisHead and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alan L HoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jens Peter KlußmannDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
Christoph AroltCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Marcel MayerDepartment of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0001-9963-1109

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Salivary gland carcinomas (SGC) are rare head and neck malignancies with diverse molecular profiles and treatment challenges. Tissue factor (TF), a transmembrane glycoprotein involved in cancer pathophysiology, has emerged as a potential therapeutic target. Objectives: The objective of this study was to investigate TF expression in SGC and its correlation with clinicopathological data. Design: A cohort of 109 SGC patients who underwent curative surgery between 1990 and 2023 was analyzed. Methods: TF expression in primaries and lymph node (LN) metastases was assessed using immunohistochemistry on tissue microarrays. Histo-scores were calculated for cytoplasmic and membranous staining and correlated with clinicopathological data. Results: TF was expressed in 80.7% of samples with a mean combined Conclusion: This study provides the first analysis of TF expression in SGC revealing its presence across various subtypes. The findings suggest potential for TF-targeted therapies in SGC treatment, particularly for metastatic SDC and MEC. The trend toward worse survival outcomes in high TF-expressing tumors warrants further investigation.

Indexed as

antibody-drug conjugatehead and neck oncologysalivary duct carcinomasalivary gland cancertargeted therapytissue factor

Identifiers

PMID40861316
PMCPMC12374091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.